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From cloning to political controversy, 
human embryonic stem cells consistently 
capture newspaper headlines. With re-
markable regenerative abilities, stem cells 
theoretically possess the potential to 
replace any diseased or damaged tissue. 
Governments around the world are now 
encouraging their top stem cell experts to 
conduct their research at home. In 2006, 
Canada succeeded in enticing 35-year-
old Mickie Bhatia to stay in his native 
country and direct its first center for 
human embryonic stem cell research, the 
Stem Cell and Cancer Research Institute 
at McMaster University in Ontario.
At McMaster, Bhatia is trying to figure 
out what controls stem cell differentiation 
and what defines their environment. He’s 
found that alterations in canonical devel-
opmental networks including the Notch, 
Wnt, and Hedgehog signaling pathways, 
alter cell differentiation (1). Swapping 
out one Wnt gene for another, for ex-
ample, can make a pluripotent cell turn 
mesodermal (2). Bhatia is also trying to 
find ways to distinguish 
between normal, pluripo-
tent, proliferative cells and 
those that lead to tumors 
(3). These so-called cancer 
stem cells may be to blame 
for the recurrence of 
cancer after therapy; they 
drive tumor growth and 
spreading, and radiation 
treatments don’t appear to 
harm them. Finally, Bhatia 
is looking to harness the 
power of stem cells with-
out encountering the eth-
ical concerns that go 
hand-in-hand with embryonic stem cell 
research by experimenting with induced 
pluripotent stem (iPS) cells derived from 
human skin–derived fibroblasts. If iPS 
cells can be reliably reprogrammed, they 
could provide all of the advantages of 
embryonic stem cells, minus ethical 
unease. Recently, Bhatia and his col-
leagues optimized iPS cell generation by 
creating markers that identify cells in the 
process of being reprogrammed (4).
How do the guidelines for using 
embryonic stem cell lines in Canada 
compare to the US?
They’re not as prescriptive as the rules 
are in the United States. You can work 
with established human embryonic stem 
cell lines as long as appropriate consent 
was given to derive those lines. And un-
like in the US, the rules that determine 
which lines can be used apply to all stem 
cell work. If you’re doing the work on 
Canadian soil, you have to follow these 
guidelines no matter where the money 
comes from.
Has the recent surge in media attention 
on stem cells as a result of US policy 
changes put additional pressure on you?
I think that now the public is going to 
want to see results. But what isn’t talked 
about enough is that we are actually at a 
very early stage of understanding. People 
may not understand that you can’t rush 
things. Science moves at its own pace. 
And you don’t want to rush it because 
history has told us that if you do, the 
science probably won’t be done very well.
Are you concerned that the science is 
being rushed?
I’m concerned about how the data are be-
ing interpreted. Right now, our main goal 
with stem cells is to make other cell types. 
We want those cells to become progeni-
tors of a specifi  c lineage that could then be 
useful in cell replacement therapies. But 
we are restricted to in vitro culture, and we 
know that a dish is not an organism. For 
example, we can generate blood cells that 
have the right phenotype and express the 
right cell surface markers, but we can’t 
make them perform [their function] (5). 
I think we’re underestimating the amount 
of work that getting them to perform will 
require. And I worry that underestimation 
leads to unrealistic promissory notes and 
timelines that the public expects.
What do you mean by perform?
We want to get pluripotent cells to diff  er-
entiate into cells like hematopoietic stem 
cells that we get from blood marrow do-
nors. We’ve now generated cells that look 
identical in every measurable feature but 
when you engraft them into an immune-
defi  cient mouse, they don’t function how 
the cell markers in the dish predicted they 
would. The cells don’t migrate to the right 
spot, they don’t move the way they should, 
there’s a variety of problems we’ve charac-
terized. So, I don’t know what the problem 
is but I can tell you what the failures are!
We do think that there might be 
some hope in using iPS cells that are 
derived from skin fibroblasts. First of all, 
by using these we can hopefully alleviate 
some ethical concerns. And I think these 
cells might actually perform a little bet-
ter because they seem to have some sort 
of memory of their adulthood. We hope 
that when you transplant them into an 
animal, they can generate the blood sys-
tem or the immune system better than 
embryonic cells can.
In a recent commentary, you referred to 
hematopoietic cells generated from 
embryonic stem cells as cartoons. Why?
I was trying to describe everyone’s 
supposed improvements on the recipes 
to make blood cells. If I come up with 
a new way to get 30% blood cells [from 
stem cell cultures], someone might call 
that an improvement if before we could 
only come up with 20% blood cells. 
But if none of these methods actually 
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regenerates the blood system, then that 
improvement doesn’t matter. We need 
them to work in reality. But as of now, 
they don’t. Fred Flintstone has a head, a 
nose, and two legs, but he can’t jump 
out of the TV and clean your house.
Do you have more hope for embryonic 
stem cells than Fred Flintstone?
Oh yeah. I mean, if you take a mouse 
embryonic stem cell, you can generate 
an entire mouse. All the potential is there. 
Our problem is that we don’t know how 
to tap into that potential in a dish. So 
I don’t think that stem cells are cartoons, 
but rather that what we generate with 
our current methods are cartoons.
RISKY TERRITORY
What do you make of the promising claims 
made by “stem cell tourists” who have 
received stem cell therapies in countries 
where it’s legal?
One of my biggest problems with stem cell 
tourism is that the places that off  er it don’t 
provide clear, defi  nable, quantitative meas-
urements of what the improvement really 
is. If the physicians or scientists adminis-
tering these therapies in a variety of places 
around the world are truly getting good 
results, then by all means, that should be 
celebrated. But what you fi  nd is that obser-
vations posted on web sites are just testi-
monies from patients and physicians. Even 
from a marketing point of view, you’d think 
that if they were having such success, they’d 
want to post data showing that patients can 
regenerate healthy cells in their blood sys-
tem, for example. And I’m not suggesting 
that people don’t feel better like they say 
they do—just as a scientist, I’m a little 
tortured by this because as long as it’s 
being done, I’d like the information to 
be shared.
Another reason why stem cell tourism 
really bothers me is that as director of a 
stem cell institute, I field a lot of calls from 
people who have children with terrible 
diseases and want to know why we aren’t 
allowing their child to undergo these ther-
apies. I can hear the logic combined with 
desperation in their voices. And it’s really 
sad because they want to do whatever it 
takes to help their child—I feel like some 
of these places are exploiting their hopes.
Has any legal stem cell research in the 
US or Canada made you uneasy?
There was a concept for a period of time 
in which people felt that they could take 
human DNA from the nucleus and insert 
it into an enucleated egg from another 
species as a way to generate embryonic 
stem cell lines. For example, one could 
take a human fi  broblast nucleus and insert 
it into a cow egg. That made me uneasy 
because I worry when good, creative 
scientists are working to sidestep policy. 
Very much like stem cell tourism, nobody 
was looking for a fundamental under-
standing of what was going on.
THE MEANS AND THE ENDS
Besides using embryonic stem cells in 
therapy, might they have another use?
It could end up that the best stem cell 
therapy may not require stem cells at 
all. We might discover new drugs that 
induce endogenous repair. Maybe 
we’ll identify chemicals that target 
stem cells remaining in damaged tis-
sue. If activating a signaling pathway 
causes pluripotent cells to become 
blood stem cells, perhaps a drug could 
be made to trigger that pathway. And if 
that drug could be administered to 
somebody who requires bone marrow 
regeneration, you wouldn’t even need 
to worry about rejection.
Also, we hope that stem cells can teach 
us about cancer. We have evidence that 
many tumors don’t respond to chemo-
therapy and/or regenerate after the tumor 
shrinks because there’s a small fraction of 
cancerous cells with stem cell–like proper-
ties. So the question becomes, what is the 
difference between normal stem cells and 
cancer stem cells? By looking at both kinds 
of cells with this incredible self-renewal 
capacity, you can make cross comparisons. 
So far we’ve characterized at least 12 crite-
ria that distinguish normal pluripotent cells 
from cancer cells. For example, the can-
cerous versions are environment indepen-
dent and no longer respond to the same 
growth factors that regulate self-renewal 
in normal stem cells. Now we are trying 
to develop novel bioactive compounds 
that will kill the cancer stem cells without 
harming normal stem cells. We’re doing 
this in an automated screening process so 
that we can sift through thousands of mol-
ecules quickly because you can’t generate 
107 or 108 leukemic stem cells or normal 
stem cells from a patient’s bone marrow.
Is there strong religious resistance to stem 
cell research in Canada?
Yes, I hear from concerned 
people all the time. And I listen 
carefully, answer questions, and 
explain how embryonic stem 
cells lines are generated—that 
human embryos used for re-
search have been consented for 
destruction and also consented 
for research purposes. I think 
this two-tiered process alleviates a lot of 
people’s fears. And, using iPS cells has 
relieved a number of concerns as well.
When does life begin?
Well, I don’t ever want to project my 
opinion over another person’s view. 
What I’m more concerned about is how 
to prevent life from ending and keeping 
the quality of life as high as possible.
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Brachyury (red) and Frizzled (green) expression 
suggest that this human embryonic stem cell 
has differentiated into a hematopoietic cell.
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“The best 
stem cell 
therapy may 
not require 
stem cells 
at all.”